Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content
Regulatory
25 June 2025

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
25 June 2025 Delisting of the shares of Scandion Oncology – last day of trading July 11, 2025 Download Presentation Webcast Workbook
25 June 2025 Scandion Oncology has applied for delisting of the company’s shares from Nasdaq First North Growth Market Download Presentation Webcast Workbook
27 March 2025 Scandion Oncology Announces Results of Annual General Meeting Download Presentation Webcast Workbook
12 March 2025 Scandion Oncology – Notice convening the Annual General Meeting Download Presentation Webcast Workbook
12 March 2025 Scandion Oncology – Annual Report 2024 Download Presentation Webcast Workbook
12 March 2025 Scandion Oncology – Q4 & yearend report 2024 Download Presentation Webcast Workbook
26 February 2025 Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report Download Presentation Webcast Workbook
20 November 2024 Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million Download Presentation Webcast Workbook
14 November 2024 Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024 Download Presentation Webcast Workbook
11 November 2024 Scandion Oncology – Interim Report Q3 2024 Download Presentation Webcast Workbook
4 November 2024 Scandion Oncology announces the start of the exercise period for warrants of series TO 2 Download Presentation Webcast Workbook
31 October 2024 Correction: Scandion Oncology announces exercise price for warrants of series TO 2 Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.